12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Benzinga · 06/12/2024 12:06
Gainers
- Avidity Biosciences (NASDAQ:RNA) shares rose 24.5% to $36.0 during Wednesday's pre-market session. The company's market cap stands at $3.4 billion.
- Molecular Partners (NASDAQ:MOLN) shares moved upwards by 18.43% to $5.91. The market value of their outstanding shares is at $196.1 million.
- Longeveron (NASDAQ:LGVN) shares increased by 15.84% to $0.95. The company's market cap stands at $6.0 million.
- TRACON Pharma (NASDAQ:TCON) shares increased by 15.74% to $1.25. The market value of their outstanding shares is at $3.3 million.
- Oramed Pharmaceuticals (NASDAQ:ORMP) stock moved upwards by 14.49% to $2.37. The market value of their outstanding shares is at $96.2 million.
- NovaBay Pharmaceuticals (AMEX:NBY) stock rose 12.72% to $3.1. The market value of their outstanding shares is at $3.5 million.
Losers
- ThermoGenesis Holdings (NASDAQ:THMO) shares decreased by 40.5% to $0.33 during Wednesday's pre-market session. The company's market cap stands at $2.6 million.
- Calidi Biotherapeutics (AMEX:CLDI) shares fell 11.86% to $0.24. The market value of their outstanding shares is at $15.2 million.
- Streamline Health Solns (NASDAQ:STRM) shares decreased by 10.94% to $0.57. The market value of their outstanding shares is at $35.4 million. As per the news, the Q1 earnings report came out yesterday.
- Tevogen Bio Holdings (NASDAQ:TVGN) shares decreased by 8.28% to $0.8. The company's market cap stands at $132.8 million.
- Cyclacel Pharmaceuticals (NASDAQ:CYCC) shares decreased by 8.11% to $1.7. The market value of their outstanding shares is at $2.4 million.
- Bright Green (NASDAQ:BGXX) stock fell 7.91% to $0.28. The market value of their outstanding shares is at $53.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.